CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

[April 15, 2014]

Research and Markets: Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/cw3gct/hexyon) has announced the addition of the "Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Hexyon [Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), inactivated poliovirus, Hib conjugate vaccine (adsorbed)] is Sanofi Pasteur MSD's hexavalent combination vaccinethat offers protection against infections caused by diphtheria, tetanus, pertussis, three subtypes of poliovirus, Hib, and all known subtypes of HBV.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Hexyon including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Hexyon for top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Canada.

Key Topics Covered:

  1. Tables & Figures
  2. Introduction
  3. Disease Overview
  4. Vaccination Recommendations and Coverage Rates
  5. Competitive Assessment
  6. Hexyon
  7. Appendix

For more information visit http://www.researchandmarkets.com/research/cw3gct/hexyon


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter